My Cart
You have no items in your shopping cart.
Background
Kir1.1 is an inwardly rectifying potassium channel expessed in kidney, skeletal muscle, liver, pancreas, spleen, and the central nervous system. Mutations in Kir1.1 are responsible for Bartter's syndrome (renal salt loss) and hereditary hypertension with hyperkalemia. Kir1.1 has therapeutic potential in treatment of hypertension.
| General Info | |
| Product Description | Human Kir1.1 potassium ion channel-expressing, transiently transfected cells. |
|---|---|
| Target Type | Ion Channel |
| Product Type | EZCells™ TT |
| Family | Potassium, Inward Rectifier |
| Sub-Type | Kir1.1 |
| Class | Inward rectifier potassium channel |
| Therapeutic Area | genitourinary |
| Gene Name | KCNJ1 |
| Validated Assay/Platform | manual patch clamp |
| References | Kubo Y, et al. 2005. Pharmacol Rev. 57:509-526. International Union of Pharmacology. LIV. Nomenclature and molecular relationships of inwardly rectifying potassium channels. |
| EZCell Info | |
| Host cell | HEK293 |
| Mycoplasma Status | Negative (MycoAlert Kit) |
| Growth media | DMEM/F12/10% FBS |
| Functional expression | Ba2+ -sensitive current amplitude at -110 mV (mean ± SEM) = 1.6 ± 0.3 nA, n = 6 manual patch clamp recordings |
| Storage and Packaging | |
| Packaging | Cryopreserved cells, 6x106 cells/vial |
| Storage Recommendation | liquid nitrogen |
| Quantity | 6 million cells |
| Media | |
| Specification Sheet |  Download PDF Document |
